Clobazam for intractable XXXX .

@entity1 @entity410 @entity308 @entity146 @entity2915 @entity302 @entity22
We report our experience with add-on clobazam therapy over a 5-year period in 63 @entity1 with @entity302 . The mean duration of @entity302 was 6.7 years. @entity1 were followed for 15 to 64 months. Of 63 @entity1 , 57 were developmentally delayed, and 54 had a symptomatic/cryptogenic @entity302 . Forty-one percent became either @entity410 free or had a greater than 90% reduction in @entity410 frequency. @entity410 frequency was reduced 50% to 90% in another 24%. The average daily dose of clobazam was 0.8 mg/kg. Thirty-five percent had the medication withdrawn for persistent or unacceptable side effects or the development of tolerance (seven @entity1 ). Side effects included severe @entity146 outbursts, @entity2915 , @entity22 , and @entity308 with suicidal ideation. Clobazam is a useful add-on medication for 65% of @entity1 with @entity302 . Clinical utility may be limited by behavioral side effects in some @entity1 .
